Recent News
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com along with interesting case questions from "Ask Cush Anything".



Zasocitinib (Tyk2 Inhibitor) Efficacy in Psoriatic Arthritis
A highly selective, tyrosine kinase 2 inhibitor zasocitinib (TAK-279), was studied in a phase 2b trial and found to be effective and safe patients with active psoriatic arthritis (PsA).
Read ArticleAmericans choose short term relief for neck and back pain
New survey data from the Orlando Health Spine Center reveals a significant difference among Americans on how to manage neck and back pain. Respondents were split between relying on rest and reduced activity (44%), turning to over-the-counter pain relievers (42%), and hot/cold therapies (29%) — an uncertainty that may be discouraging some from seeking medical guidance.
Read Article



Links:

Molecular profiling of RA synovium predicts biologic responses
Machine learning analysis of pre-treatment synovial tissue biopsy from rheumatoid arthritis (RA) patients starting either etanercept (ETN), tocilizumab (TCZ) and rituximab (RTX) revealed high accuracy prediction of 16 week outcomes unique to each biologic.
1 in 5 Patients are Unaware of their Arthritis Diagnosis
Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA. Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).
This most recent analysis of the prevalence and distribution of arthritis subtypes in the US, used data from NHANES 2020 (National Health and Nutrition Examination Survey) that collected data from 2017 to March 2020 .
Read Article
Links:




Links:

Links:

